(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a Radiopharmaceutical Therapy Trials with Dosimetry session. Dr.

In a prostate cancer mouse model (22Rv1 xenografts), the combination of 225 Ac-YS5 (0.12 µCi) + YS5-MMAE (1.8 mg/kg) was associated with the most significant reduction in tumor volume (green curves in ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a session on non-beta emitter PSMA radioligand therapy. Dr.

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a session on non-beta emitter PSMA radioligand therapy. Dr. David ...

(UroToday.com) The Interdisciplinary Genitourinary Cancer Forum 2025, held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 2: Local Treatments. Dr. Peter Carroll ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

Additionally, multivariable analyses demonstrated that detectable ctDNA before radical cystectomy was associated with a higher risk of nodal disease (OR 5.4, 95% CI 1.9-18.2; p = 0.003) and locally ...

artificial intelligence can simplify complex radiopharmaceutical dosimetry procedures, AI-powered image enhancement, automated segmentation, registration improvement, direct dose map calculation ...

ASCO 2025 Phase 3 AMPLITUDE trial, Niraparib and abiraterone acetate plus prednisone, metastatic castration-sensitive prostate cancer, alterations in homologous recombination repair genes.

Pedro Barata speaks with Tian Zhang about the PDIGREE phase III adaptive trial. This cooperative group study enrolled over 1,000 patients across 46 states over five years, representing a collaborative ...

ASCO 2025 multimodal artificial intelligence (MMAI) model, androgen receptor pathway inhibitors (ARPI), high-risk non-metastatic prostate cancer, STAMPEDE.